Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Seynaeve

Showing results (61-70 of 104) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patientsP M L H Vencken, M Kriege, D Hoogwerf, et al.
Critical Reviews in Oncology/Hematology|July 17, 2012
Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guidelineF Y F L De Vos, H W M van Laarhoven, J S E Laven, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomyP J C Bresser, C Seynaeve, A R Van Gool, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2006
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testingI van Oostrom, H Meijers-Heijboer, H J Duivenvoorden, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 3, 2002
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutationC M E Contant, M B E Menke-Pluijmers, C Seynaeve, et al.
Clinical Genetics|January 6, 2007
Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective studyI van Oostrom, H Meijers-Heijboer, H J Duivenvoorden, et al.
Lancet (London, England)|July 8, 2000
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutationE J Meijers-Heijboer, L C Verhoog, C T Brekelmans, et al.
British Journal of Cancer|August 12, 2010
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerL A Lammers, R H J Mathijssen, T van Gelder, et al.
British Journal of Cancer|June 12, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapyM Kriege, A Hollestelle, A Jager, et al.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Pageof 11

Showing results (61-70 of 104) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 14, 2011
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patientsP M L H Vencken, M Kriege, D Hoogwerf, et al.
Critical Reviews in Oncology/Hematology|July 17, 2012
Menopausal status and adjuvant hormonal therapy for breast cancer patients: a practical guidelineF Y F L De Vos, H W M van Laarhoven, J S E Laven, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2006
The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomyP J C Bresser, C Seynaeve, A R Van Gool, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2006
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testingI van Oostrom, H Meijers-Heijboer, H J Duivenvoorden, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 3, 2002
Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutationC M E Contant, M B E Menke-Pluijmers, C Seynaeve, et al.
Clinical Genetics|January 6, 2007
Family system characteristics and psychological adjustment to cancer susceptibility genetic testing: a prospective studyI van Oostrom, H Meijers-Heijboer, H J Duivenvoorden, et al.
Lancet (London, England)|July 8, 2000
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutationE J Meijers-Heijboer, L C Verhoog, C T Brekelmans, et al.
British Journal of Cancer|August 12, 2010
The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerL A Lammers, R H J Mathijssen, T van Gelder, et al.
British Journal of Cancer|June 12, 2014
Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapyM Kriege, A Hollestelle, A Jager, et al.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Pageof 11